Scientific recommendation on classification of advanced therapy medicinal products


Disclaimer: This document is a summary for public release of a scientific recommendation on classification of advanced therapy medicinal products. The original text adopted by the Committee for Advanced Therapies (CAT) has been redacted to delete commercially confidential information.

The present scientific recommendation refers exclusively to the case as presented to the European Medicines Agency (EMA) without prejudice to future evaluations by the Agency.

It is stressed that the scientific recommendation on advanced therapy classification does not amount to any endorsement of the plausibility of the product, including the mode of action or therapeutic indication(s) claimed by the applicant.

Brief description (or name when available) of the active substance(s)

Messenger RNAs (mRNAs) encoding immunostimulatory proteins caTLR4, CD40L and CD70 and tumour associated antigens (TAA) tyrosinase, gp100, MAGE A3, MAGE C2 and PRAME.

Brief description of the finished product

Concentrate for solution for injection for parenteral administration.

Proposed indication

Treatment of melanoma.

EMA/CAT conclusion

The procedure was finalised on 14 September 2017 for the following recommendation.

On the basis that the product:

- contains an active substance that consist of a recombinant nucleic acid molecules of biologic origin;
• is intended to be administered to human beings with a view to adding a genetic sequence;
• is therapeutic effect relates directly to the product of genetic expression of this sequence,

the EMA/CAT considers that the product falls within the definition of a gene therapy medicinal product as provided in Article 2(1) of Regulation (EC) 1394/2007.